{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.6","upperLimit":"2.0","value":"1.8"},{"groupId":"OG001","lowerLimit":"1.5","upperLimit":"2.0","value":"1.8"},{"groupId":"OG002","lowerLimit":"1.2","upperLimit":"3.6","value":"1.4"},{"groupId":"OG003","lowerLimit":"1.6","upperLimit":"1.9","value":"1.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"97"}],"units":"Participants"}],"description":"PFS is calculated as 1+ the number of days from the first dose of study drug to disease progression by RECIST, as determined by the investigator or death due to any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with HRD status unknown who received continuous dosing with rucaparib 600 mg twice a day (BID) in 28-day cycles. Patients whose tumor genome-wide LOH was not tested or not determined were considered HRD unknown.","id":"OG000","title":"HRD Unknown"},{"description":"Patients with HRD status negative who received continuous dosing with rucaparib 600 mg twice a day (BID) in 28-day cycles. Patients whose tumor had genome-wide LOH \\< 10% were considered HRD-negative.","id":"OG001","title":"HRD Negative"},{"description":"Patients with HRD status positive who received continuous dosing with rucaparib 600 mg twice a day (BID) in 28-day cycles. Patients whose tumor had genome-wide LOH ≥ 10% were considered HRD-positive.","id":"OG002","title":"HRD Positive"},{"description":"All patients","id":"OG003","title":"Overall"}],"paramType":"MEDIAN","populationDescription":"Intent-to-Treat population - all patients who received at least 1 dose of rucaparib","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 to End of Treatment, up to approximately 10 months","title":"Progression-free Survival (PFS) According to RECIST v1.1, as Assessed by the Investigator","type":"SECONDARY","unitOfMeasure":"months"}